SFEBES2016 Poster Presentations Thyroid (26 abstracts)
Thyroid autoimmunity as a biomarker of breast cancer outcome: large-scale study using data from the Taxotere as Adjuvant Chemotherapy Trial (TACT: CRUK01/001)
Ilaria Muller 1 , Lucy Kilburn 2 , Peter Taylor 1 , Peter Barrett-Lee 3 , Judith Bliss 2 , Ellis Paul 4 , Ludgate Marian 1 & Colin Dayan 1
1Thyroid Research Group, Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, UK; 2The Institute of Cancer Research – Clinical Trials & Statistics Unit (ICR-CTSU), London, UK; 3Breast Cancer Centre, Velindre NHS Trust, Cardiff, UK; 4Guy’s Hospital & King’s College, London, UK.
Background: An association between breast cancer (BC) and thyroid autoimmunity has been frequently observed, and several small-scale studies correlated the presence of autoantibodies to thyroid peroxidase (TPOAb) with an improved BC outcome. We aimed to clarify in a large cohort of patients whether circulating TPOAb are prognostic for BC recurrence.
Materials and methods: Available plasma samples for patients with node-positive or high-risk node-negative early BC previously enrolled in TACT trial (Ellis et al. Lancet 2009, Bliss et al. Cancer Res Suppl. 2012) were measured (standard assays) for TPOAb (positive ≥6kU/L), free-thyroxine and thyroid stimulating hormone (combined as euthyroid, hypothyroid, hyperthyroid status). Prognostic significance of these markers was assessed for disease free survival (DFS), overall survival (OS) and time to recurrence (TTR) using Cox regression models stratified by chemotherapy regimen and ER status. Univariate and multivariable analyses were performed, considering other known prognostic factors for BC (nodal status, HER2 status, age, tumour grade, tumour size) and type of surgery.
Results: 1974 (47.4%) patients had plasma available, taken 15.5 months (median) after BC surgery, with majority taken during/after adjuvant treatment for BC. 406 (20.6%) patients were TPOAb positive. The median follow-up was 96.7 months. There was no evidence of difference in DFS by TPOAb status (unadjusted hazard ratio [HR]=0.97, 95%CI: 0.78–1.19; P=0.75) and/or thyroid function (unadjusted HR (hypothyroid versus normal) =1.15 95%CI: 0.79–1.68; P=0.46, HR (hyperthyroid versus normal)=1.14, 95%CI: 0.82–1.61; P=0.44). Similar results were obtained for OS and TTR. Sensitivity analyses in a 123 patients subgroup with plasma collected before BC adjuvant therapy also showed no evidence of TPOAb prognostic ability.
Conclusions: No evidence for a prognostic role of TPOAb and/or thyroid function in moderate-high risk early BC was found in the largest and longest observational study to date. Confounding due to BC adjuvant treatments is unlikely.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more